Zorevunersen in Children and Adolescents with Dravet Syndrome

20262 citationsJournal Articlegreen Open Access

Authors

Linda C. Laux · Lurie Children's Hospital

Joseph Sullivan · UCSF Benioff Children's Hospital

M. Scott Perry · Cook Children's Medical Center

Andreas Brunklaus · University of Glasgow

Archana Desurkar · Sheffield Children's NHS Foundation Trust

John M. Schreiber · Children's National

Colin M. Roberts

Abstract

The safety profile and initial clinical improvement support the continued development of zorevunersen as a potential disease-modifying treatment for Dravet syndrome. (Supported by Stoke Therapeutics; MONARCH and SWALLOWTAIL ClinicalTrials.gov numbers, NCT04442295 and NCT04740476, respectively; ADMIRAL and LONGWING ISRCTN Registry numbers, ISRCTN99651026 and ISRCTN12811235, respectively.).

Topics & Keywords

Epilepsy research and treatment Advanced Neuroimaging Techniques and Applications Fetal and Pediatric Neurological Disorders

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 10, pp. 969-982

DOI: 10.1056/nejmoa2506295

Field-Weighted Citation Impact: 62.98